BIOVENTIX PLC

Pre-Annual General Meeting Information • Nov 16, 2020

National Storage Mechanism | Additional information

Bioventix Plc - Posting of Annual Report and Notice of AGM

PR Newswire

London, November 16

Bioventix plc

(“Bioventix” or the “Company”)

Posting of Annual Report and Notice of AGM

Bioventix plc (BVXP), a UK company specialising in the development and commercial supply of high-affinity monoclonal antibodies for applications in clinical diagnostics, and development company confirms that its Annual Report and Accounts for the year ended 30 June 2020 and the Notice of Annual General Meeting (“AGM”) has been posted to shareholders.

These documents are available on the Company's website at www.bioventix.com.

The AGM will be held electronically at 2.00 p.m. on 10 December 2020.

As a result of the current UK Government guidance on social distancing and prohibiting public gathering over certain numbers, the Company has taken the decision that this year unfortunately it will not be possible for shareholders to attend the AGM.

Details on how shareholders can vote by proxy are set out in the Notice of Annual General Meeting. The Company therefore requests that shareholders appoint the Chairman of the meeting as a proxy and provide their voting responses in advance of the AGM.

For further information please contact:

Bioventix plc Peter Harrison	Chief Executive Officer	Tel: 01252 728 001
finnCap Ltd Geoff Nash/Simon Hicks Alice Lane	Corporate Finance ECM	Tel: 020 7220 0500

About Bioventix plc:

Bioventix (www.bioventix.com) specialises in the development and commercial supply of high-affinity monoclonal antibodies with a primary focus on their application in clinical diagnostics, such as in automated immunoassays used in blood testing. The antibodies created at Bioventix are generated in sheep and are of particular benefit where the target is present at low concentration and where conventional monoclonal or polyclonal antibodies have failed to produce a suitable reagent. Bioventix currently offers a portfolio of antibodies to customers for both commercial use and R&D purposes, for the diagnosis or monitoring of a broad range of conditions, including heart disease, cancer, fertility, thyroid function and drug abuse. Bioventix currently supplies antibody products and services to the majority of multinational clinical diagnostics companies. Bioventix is based in Farnham, UK and its shares are traded on AIM under the symbol BVXP.